+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiviral Drugs Market by Indication (Hepatitis B, Hepatitis C, Herpes Simplex), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Non Nucleoside Reverse Transcriptase Inhibitors), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Antiviral Drugs Market by Indication (Hepatitis B, Hepatitis C, Herpes Simplex), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Non Nucleoside Reverse Transcriptase Inhibitors), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Antiviral Drugs Market by Indication (Hepatitis B, Hepatitis C, Herpes Simplex), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Non Nucleoside Reverse Transcriptase Inhibitors), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904660
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antiviral drugs market is navigating a complex landscape shaped by scientific innovation, evolving health threats, and regulatory shifts. Senior decision-makers must understand how emerging technologies, shifting supply chains, and policy changes impact both strategic planning and operational execution in this dynamic sector.

Market Snapshot: Antiviral Drugs Market Outlook

The Antiviral Drugs Market grew from USD 59.84 billion in 2024 to USD 63.81 billion in 2025. It is expected to continue growing at a CAGR of 6.57%, reaching USD 87.67 billion by 2030. This growth is underpinned by rapid advances in molecular biology, heightened demand following recent epidemics, and the expanding role of personalized treatment strategies. Ongoing challenges, such as viral mutations and resistant strains, reinforce the need for robust R&D pipelines and diversified supply networks. Global healthcare systems are prioritizing access to advanced antivirals as investment in scalable delivery and technology platforms accelerates worldwide adoption.

Scope & Segmentation of the Antiviral Drugs Market

This report delivers a multidimensional analysis, offering a detailed segmentation by indication, drug class, administration route, distribution channel, end user, and region, as well as a review of leading companies and enabling technologies.

  • Indication: Hepatitis B, Hepatitis C, Herpes Simplex, HIV, Influenza, Respiratory Syncytial Virus
  • Drug Class: Fusion Inhibitors, Integrase Inhibitors, Non Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Analogues, Protease Inhibitors
  • Route of Administration: Inhalation, Injectable, Oral, Topical
  • Distribution Channel: Clinics, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End User: Clinics, Home Care, Hospitals, Long Term Care Facilities
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (covering more than 20 countries, including United Kingdom, Germany, France, South Africa, Saudi Arabia, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, and additional markets)
  • Leading Companies: Gilead Sciences, Inc.; AbbVie Inc.; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; GlaxoSmithKline plc; Pfizer Inc.; Johnson & Johnson; Bristol-Myers Squibb Company; ViiV Healthcare Limited; AstraZeneca plc
  • Key Technologies: mRNA platforms, AI-powered drug discovery, genomics, digital health solutions, blockchain-enabled supply chain management, companion diagnostics

Key Takeaways for Decision-Makers

  • Advances in mRNA, AI-based tools, and real-world data collection are enabling quicker identification and accelerated development of novel antiviral agents suited for current and emerging viral threats.
  • Cross-sector partnerships, particularly between biotech firms, government, and academia, are catalyzing access to cutting-edge therapies and fostering portfolio innovation across regions.
  • Personalized therapy regimens are gaining traction as digital health platforms enhance patient adherence and connect clinical outcomes with precise viral diagnostics.
  • Stakeholder strategies increasingly emphasize supply chain agility, including nearshoring and diversified sourcing, to address vulnerabilities revealed by recent global disruptions.
  • Patient access initiatives—such as tiered pricing, expanded assistance programs, and collaboration with public sector partners—are critical for bridging care gaps, especially in low- and middle-income settings.
  • Market segmentation reveals opportunities in high-need areas like hepatitis and HIV, while respiratory viruses and topical formulations offer targeted growth potential amid evolving pandemic responses.

Tariff Impact: Navigating 2025 Policy Shifts

The introduction of United States tariffs on pharmaceutical imports in 2025 has prompted manufacturers to rethink sourcing and pricing strategies. Companies are strengthening inventory controls, investing in traceability solutions, and exploring regional production partnerships to cushion against increased material and operational costs. These measures help ensure continuity of supply and sustained access to critical therapies for patients worldwide while building resilience into global antiviral drug supply chains.

Methodology & Data Sources

This analysis integrates primary research through structured interviews with sector leaders and surveys with clinicians. Secondary research spans peer-reviewed literature, regulatory files, and corporate disclosures. Data validation relied on triangulation and cross-referencing ahead of in-depth PESTLE, SWOT, and Porter’s Five Forces assessments.

Why This Report Matters

  • Equips senior decision-makers with in-depth, actionable intelligence for investment, innovation, and operational planning in the antiviral drugs sector.
  • Provides a comprehensive roadmap for portfolio alignment, technology adoption, and regional expansion based on a current assessment of global and segment-specific dynamics.
  • Delivers early insight into emerging policy and pricing trends, helping companies secure a competitive edge and optimize patient access strategies.

Conclusion

The antiviral drugs market is redefined by rapid scientific progress, policy shifts, and diverse patient needs. By harnessing evidenced-based insights and aligning with innovation-driven imperatives, leaders can advance both access and growth in this evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of long-acting injectable antiviral therapies for HIV prevention and treatment
5.2. Expansion of direct-acting antiviral regimens for hepatitis C in resource-limited settings
5.3. Development of broad-spectrum antiviral agents targeting conserved viral polymerases and proteases
5.4. Growth of monoclonal antibody prophylactics for respiratory syncytial virus in high-risk pediatric populations
5.5. Integration of artificial intelligence and machine learning in antiviral drug discovery and repurposing efforts
5.6. Emergence of combination antiviral therapies enhancing potency against drug-resistant influenza strains
5.7. Increased investment in pan-coronavirus therapeutic platforms for pandemic preparedness
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antiviral Drugs Market, by Indication
8.1. Introduction
8.2. Hepatitis B
8.3. Hepatitis C
8.4. Herpes Simplex
8.5. Hiv
8.6. Influenza
8.7. Respiratory Syncytial Virus
9. Antiviral Drugs Market, by Drug Class
9.1. Introduction
9.2. Fusion Inhibitors
9.3. Integrase Inhibitors
9.4. Non Nucleoside Reverse Transcriptase Inhibitors
9.5. Nucleoside Analogues
9.6. Protease Inhibitors
10. Antiviral Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Inhalation
10.3. Injectable
10.4. Oral
10.5. Topical
11. Antiviral Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Clinics
11.3. Hospital Pharmacies
11.4. Online Pharmacies
11.5. Retail Pharmacies
12. Antiviral Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
12.5. Long Term Care Facilities
13. Americas Antiviral Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Antiviral Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Antiviral Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Gilead Sciences, Inc.
16.3.2. AbbVie Inc.
16.3.3. F. Hoffmann-La Roche Ltd
16.3.4. Merck & Co., Inc.
16.3.5. GlaxoSmithKline plc
16.3.6. Pfizer Inc.
16.3.7. Johnson & Johnson
16.3.8. Bristol-Myers Squibb Company
16.3.9. ViiV Healthcare Limited
16.3.10. AstraZeneca plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTIVIRAL DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ANTIVIRAL DRUGS MARKET: RESEARCHAI
FIGURE 26. ANTIVIRAL DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. ANTIVIRAL DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. ANTIVIRAL DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 89. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 92. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 93. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 102. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 103. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 164. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 165. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 174. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 175. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 194. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 195. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 214. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 224. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 264. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 265. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 274. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 275. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 284. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 285. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 304. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 305. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 314. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 315. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 324. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 325. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 328. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 329. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 330. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 331. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 334. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 335. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 336. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 337. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 338. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 339. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 340. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 341. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 342. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 343. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 344. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 345. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 346. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 347. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 348. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 349. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 350. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 351. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 352. ASIA-PACI

Samples

Loading
LOADING...

Companies Mentioned

  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • ViiV Healthcare Limited
  • AstraZeneca plc

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 63.81 Billion
Forecasted Market Value ( USD ) by 2030 $ 87.67 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Antiviral Therapeutics Market by Disease Type (Covid-19, Cytomegalovirus, Hepatitis C), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Interferons), Route Of Administration, Distribution Channel, Therapy Type - Global Forecast 2025-2030 - Product Image

Antiviral Therapeutics Market by Disease Type (Covid-19, Cytomegalovirus, Hepatitis C), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Interferons), Route Of Administration, Distribution Channel, Therapy Type - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Direct-acting Antiviral Drug Market by Product Type (Branded Drugs, Generic Drugs), Therapeutic Class (Combination Therapy, Ns5A Inhibitor, Ns5B Inhibitor), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Direct-acting Antiviral Drug Market by Product Type (Branded Drugs, Generic Drugs), Therapeutic Class (Combination Therapy, Ns5A Inhibitor, Ns5B Inhibitor), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Specific Antiviral Drugs For COVID 19 Global Market Report 2025 - Product Image

Specific Antiviral Drugs For COVID 19 Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Antiviral Combination Therapy Market Report 2025 - Product Image

Antiviral Combination Therapy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 135 Pages
  • Global
From

About the Antivirals Market

The Antivirals market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat viral infections. Antivirals are used to treat a wide range of viral infections, including influenza, HIV, herpes, hepatitis, and other respiratory infections. Antivirals work by targeting the virus itself, preventing it from replicating and spreading throughout the body. They can also be used to reduce the severity of symptoms and shorten the duration of the illness. Antivirals are typically administered orally or intravenously, depending on the type of virus and the severity of the infection. In some cases, antivirals may be used in combination with other drugs to increase their effectiveness. Some of the major companies in the Antivirals market include Gilead Sciences, Merck & Co., Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb. These companies produce a variety of antiviral drugs, including those used to treat influenza, HIV, herpes, and hepatitis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.